PD-L1 gene amplification and focality: relationship with protein expression

被引:5
|
作者
Jardim, Denis Leonardo [1 ]
Murugesan, Karthikeyan [2 ,3 ]
Elvin, Julia A. [3 ]
Huang, Richard S. P. [3 ]
Kurzrock, Razelle [4 ,5 ]
机构
[1] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
[2] Fdn Med Inc, Canc Genom Res, Cambridge, MA USA
[3] Fdn Med Inc, Cambridge, MA USA
[4] WIN Consortium Personalized Canc Therapy, Dept Med, San Diego, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI USA
关键词
Biomarkers; Tumor; Genetic Markers; Immunohistochemistry;
D O I
10.1136/jitc-2022-006311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PD-L1 (CD274) amplification occurs in a small subset of malignancies and may predict anti-PD-1/PD-L1 immunotherapy responsiveness. We hypothesized that both copy number (CN) and focality of cancer-related PD-L1 amplifications impact protein expression, and, thus, analyzed solid tumors that underwent comprehensive genomic profiling between March 2016 and February 2022 at Foundation Medicine. PD-L1 CN alterations were detected using a comparative genomic hybridization-like method. PD-L1 CN changes were correlated with PD-L1 protein expression (DAKO 22C3 antibody) by immunohistochemistry (IHC). Overall, 60,793 samples were analyzed (most frequent histologies: lung adenocarcinoma (20%), colon adenocarcinoma (12%), lung squamous carcinoma (8%)). Using a definition of CD274 CN >= specimen ploidy +4 (6 copies), 1.21% of tumors (738/60,793) were PD-L1 amplified. Focality category distribution was as follows: <0.1 mB (n=18 (2.4%)), >= 0.1 to <4 mB (n=230 (31.1%)), >= 4 to <20 mB (n=310 (42%)), >= 20mB (n=180 (24.4%)). Lower levels of PD-L1 amplification (below specimen ploidy +4) were more frequently non-focal amplifications compared to higher levels. In addition, more focal amplification (<0.1 mB) correlated with higher PD-L1 IHC expression. Median tumor proportion score (TPS) for samples with PD-L1 amplification (ploidy >=+4) according to focality were 87.5% (<0.1 mB), 80% (>= 0.1 to <4 mB), 40% (>= 4 to <20 mB), 1% (>= 20mB). In specimens with PD-L1 ploidy less than +4, but highly focal (<0.1 mB), the 75th percentile of PD-L1 expression by TPS was 80%. Conversely, non-focal (>= 20 mB) PD-L1 amplification (ploidy >=+4) can present high PD-L1 expression (TPS >= 50%), albeit infrequently (0.09% of our cohort). In conclusion, PD-L1 expression measured by IHC is influenced by PD-L1 amplification level and focality. Further correlation between amplification, focality, protein expression and therapeutic outcome for PD-L1 and other targetable genes warrants exploration.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
    Chen, Meixuan
    Pockaj, Barbara
    Andreozzi, Mariacarla
    Barrett, Michael T.
    Krishna, Sri
    Eaton, Seron
    Niu, Ruifang
    Anderson, Karen S.
    CLINICAL BREAST CANCER, 2018, 18 (05) : E1205 - E1215
  • [22] A gene polymorphism in PD-L1 promoter region is not associated with PD-L1 expression and patients' survival in gastric cancer
    Wang, Weili
    Liao, Ping
    He, Yijing
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (10) : 1379 - 1381
  • [23] A gene polymorphism in PD-L1 promoter region is not associated with PD-L1 expression and patients’ survival in gastric cancer
    Weili Wang
    Ping Liao
    Yijing He
    Cancer Immunology, Immunotherapy, 2017, 66 : 1379 - 1381
  • [24] Pembrolizumab for ED SCLC: Efficacy and Relationship with PD-L1 Expression
    Ott, Patrick A.
    Elez, Elenea
    Hiret, Sandrine
    Kim, Dong-Wan
    Moss, Rebecca A.
    Winser, Tammy
    Yuan, Shuai Sammy
    Dolled-Filhart, Marisa
    Cheng, Jonathan
    Piperdi, Bilal
    Mehnert, Janice M.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S193 - S193
  • [25] PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile
    Pizarro, Carolina
    Garcia-Diaz, Diego F.
    Codner, Ethel
    Salas-Perez, Francisca
    Carrasco, Elena
    Perez-Bravo, Francisco
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (08) : 761 - 766
  • [26] PD-L1 Expression in Sarcomas
    Kosemehmetoglu, Kemal
    Ozogul, Ece
    Babaoglu, Berrin Buyukeren
    Tezel, Gaye Y. Guler
    Gedikoglu, Gokhan M.
    LABORATORY INVESTIGATION, 2017, 97 : 18A - 18A
  • [27] PD-L1 expression in meningiomas
    Johnson, Mahlon D.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2018, 57 : 149 - 151
  • [28] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [29] PD-L1 expression of medulloblastoma
    Cakmak, P.
    Kolay, E.
    Poyraz, A.
    VIRCHOWS ARCHIV, 2018, 473 : S28 - S28
  • [30] PD-L1 Expression in Mastocytosis
    Williams, Margaret
    Lidke, Diane S.
    Hartmann, Karin
    George, Tracy I.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)